Related references
Note: Only part of the references are listed.Three years of experience: the Italian registry and safety data update
G. L. Mancardi et al.
NEUROLOGICAL SCIENCES (2011)
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society
A. Ghezzi et al.
NEUROLOGICAL SCIENCES (2011)
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
P. W. O'Connor et al.
NEUROLOGY (2011)
Natalizumab Dosage Suspension: Are We Helping or Hurting?
Timothy W. West et al.
ANNALS OF NEUROLOGY (2010)
Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice
Olivier Outteryck et al.
JOURNAL OF NEUROLOGY (2010)
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
Eva Havrdova et al.
LANCET NEUROLOGY (2009)
Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri (R)) in inflammatory diseases
Olaf Stueve et al.
CNS DRUG REVIEWS (2007)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A controlled trial of natalizumab for relapsing multiple sclerosis.
DH Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
